What is Puma Biotechnology Inc's earnings per share (EPS)?

Puma Biotechnology Inc (PBYI) reported diluted earnings per share of $0.61 for fiscal year 2025. This represents a -1.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Puma Biotechnology Inc Financials

PBYI

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Puma Biotechnology Inc (PBYI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 60/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Puma Biotechnology Inc has an operating margin of 16.3%, meaning the company retains $16 of operating profit per $100 of revenue. This results in a moderate score of 59/100, indicating healthy but not exceptional operating efficiency. This is up from 13.4% the prior year.

Growth

Puma Biotechnology Inc's revenue declined 0.9% year-over-year, from $230.5M to $228.4M. This contraction results in a growth score of 32/100.

Leverage

100

Puma Biotechnology Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Puma Biotechnology Inc's current ratio of 2.00 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Puma Biotechnology Inc converts 18.3% of revenue into free cash flow ($41.7M). This strong cash generation earns a score of 71/100.

Returns

Puma Biotechnology Inc's ROE of 23.9% shows moderate profitability relative to equity, earning a score of 64/100. This is down from 32.9% the prior year.

Altman Z-Score Distress

-3.46

Puma Biotechnology Inc scores -3.46, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($396.8M) relative to total liabilities ($86.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Strong

7/9

Puma Biotechnology Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.34x

For every $1 of reported earnings, Puma Biotechnology Inc generates $1.34 in operating cash flow ($41.8M OCF vs $31.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.6x

Puma Biotechnology Inc earns $5.6 in operating income for every $1 of interest expense ($37.3M vs $6.6M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$228.4M

YoY-0.9%

5Y CAGR+0.3%

Puma Biotechnology Inc generated $228.4M in revenue in fiscal year 2025. This represents a decrease of 0.9% from the prior year.

EBITDA

$48.2M

YoY+13.5%

Puma Biotechnology Inc's EBITDA was $48.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.5% from the prior year.

Net Income

$31.1M

YoY+2.8%

Puma Biotechnology Inc reported $31.1M in net income in fiscal year 2025. This represents an increase of 2.8% from the prior year.

EPS (Diluted)

$0.61

YoY-1.6%

Puma Biotechnology Inc earned $0.61 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$41.7M

YoY+7.4%

5Y CAGR+124.8%

Puma Biotechnology Inc generated $41.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 7.4% from the prior year.

Cash & Debt

$29.6M

YoY-57.2%

5Y CAGR-19.1%

10Y CAGR-0.6%

Puma Biotechnology Inc held $29.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

50M

YoY+2.7%

5Y CAGR+4.7%

10Y CAGR+4.5%

Puma Biotechnology Inc had 50M shares outstanding in fiscal year 2025. This represents an increase of 2.7% from the prior year.

Margins & Returns

Gross Margin

74.5%

YoY+2.5pp

5Y CAGR-8.0pp

Puma Biotechnology Inc's gross margin was 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 2.5 percentage points from the prior year.

Operating Margin

16.3%

YoY+2.9pp

5Y CAGR+29.8pp

Puma Biotechnology Inc's operating margin was 16.3% in fiscal year 2025, reflecting core business profitability. This is up 2.9 percentage points from the prior year.

Net Margin

13.6%

YoY+0.5pp

5Y CAGR+40.3pp

Puma Biotechnology Inc's net profit margin was 13.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 0.5 percentage points from the prior year.

Return on Equity

23.9%

YoY-9.0pp

10Y CAGR+140.0pp

Puma Biotechnology Inc's ROE was 23.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$62.1M

YoY+13.0%

5Y CAGR-8.7%

10Y CAGR-11.4%

Puma Biotechnology Inc invested $62.1M in research and development in fiscal year 2025. This represents an increase of 13.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$71K

YoY+26.8%

5Y CAGR+9.1%

10Y CAGR-23.3%

Puma Biotechnology Inc invested $71K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 26.8% from the prior year.

PBYI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$228.4M-0.9%	$230.5M-2.2%	$235.6M+3.3%	$228.0M-9.9%	$253.2M+12.5%	$225.1M
Cost of Revenue	$58.2M-9.7%	$64.4M+2.7%	$62.7M+13.8%	$55.1M-13.5%	$63.7M+61.8%	$39.4M
Gross Profit	$170.2M+2.5%	$166.1M-4.0%	$173.0M0.0%	$172.9M-8.7%	$189.5M+2.0%	$185.7M
R&D Expenses	$62.1M+13.0%	$54.9M+9.0%	$50.4M-3.6%	$52.2M-27.3%	$71.9M-26.4%	$97.7M
SG&A Expenses	$70.8M-11.6%	$80.2M-10.9%	$89.9M-0.1%	$90.0M-22.6%	$116.3M-1.9%	$118.5M
Operating Income	$37.3M+20.5%	$31.0M-5.1%	$32.6M+37.6%	$23.7M+1738.8%	$1.3M+104.2%	-$30.4M
Interest Expense	$6.6M-46.8%	$12.5M-6.6%	$13.3M+15.0%	$11.6M-9.5%	$12.8M-8.8%	$14.0M
Income Tax	$4.7M+175.6%	-$6.2M-670.5%	$1.1M+138.0%	$455K+40.4%	$324K+56.5%	$207K
Net Income	$31.1M+2.8%	$30.3M+40.2%	$21.6M+1079450.0%	$2K+100.0%	-$29.1M+51.5%	-$60.0M
EPS (Diluted)	$0.61-1.6%	$0.62+37.8%	$0.45	$0.00+100.0%	$-0.72+52.6%	$-1.52

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$75.5M+38.5%	$54.5M+3.9%	$52.4M+14.0%	$46.0M-22.1%	$59.1M-26.7%	$80.5M+71.1%	$47.1M+7.6%	$43.8M
Cost of Revenue	$23.1M+90.0%	$12.2M-1.0%	$12.3M+16.5%	$10.6M-24.2%	$13.9M-52.2%	$29.1M+173.0%	$10.7M-0.7%	$10.7M
Gross Profit	$52.3M+23.7%	$42.3M+5.4%	$40.1M+13.2%	$35.5M-21.5%	$45.2M-12.2%	$51.4M+41.2%	$36.4M+10.3%	$33.0M
R&D Expenses	$16.8M+5.8%	$15.9M+3.0%	$15.5M+11.5%	$13.9M-8.6%	$15.2M+20.9%	$12.5M-8.0%	$13.6M+0.3%	$13.6M
SG&A Expenses	$18.4M+9.3%	$16.8M-6.8%	$18.0M+2.5%	$17.6M+5.9%	$16.6M-1.2%	$16.8M-32.6%	$25.0M+14.8%	$21.8M
Operating Income	$17.1M+78.7%	$9.6M+44.3%	$6.6M+66.6%	$4.0M-70.2%	$13.4M-39.5%	$22.1M+1113.3%	-$2.2M+5.2%	-$2.3M
Interest Expense	$1.1M-24.8%	$1.5M-18.9%	$1.8M-15.6%	$2.2M-16.9%	$2.6M-15.5%	$3.1M-8.1%	$3.4M+0.4%	$3.4M
Income Tax	N/A	N/A	N/A	N/A	-$7.1M-2528.5%	$291K-23.0%	$378K+71.8%	$220K
Net Income	$13.4M+51.9%	$8.8M+51.1%	$5.9M+96.9%	$3.0M-84.6%	$19.3M-5.0%	$20.3M+548.6%	-$4.5M+5.9%	-$4.8M
EPS (Diluted)	N/A	$0.17+41.7%	$0.12+100.0%	$0.06	N/A	$0.41+555.6%	$-0.09+10.0%	$-0.10

PBYI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$216.3M+1.4%	$213.3M-7.5%	$230.5M+3.8%	$222.1M-2.0%	$226.6M-7.2%	$244.2M
Current Assets	$162.7M+10.2%	$147.7M-5.5%	$156.2M+16.3%	$134.3M-4.1%	$140.0M-4.2%	$146.1M
Cash & Equivalents	$29.6M-57.2%	$69.2M-18.2%	$84.6M+11.0%	$76.2M+20.7%	$63.1M-26.0%	$85.3M
Inventory	$5.5M-36.8%	$8.7M+23.2%	$7.1M+56.4%	$4.5M-36.3%	$7.1M+105.8%	$3.5M
Accounts Receivable	$53.7M+67.6%	$32.0M-33.1%	$47.8M+18.6%	$40.4M+24.1%	$32.5M+27.3%	$25.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$86.0M-29.1%	$121.2M-31.6%	$177.1M-11.7%	$200.5M-12.5%	$229.0M-8.5%	$250.2M
Current Liabilities	$81.3M-15.5%	$96.1M-3.3%	$99.4M+28.3%	$77.5M-29.3%	$109.6M-4.1%	$114.3M
Long-Term Debt	$0-100.0%	$21.7M-66.9%	$65.7M-33.2%	$98.3M+1.3%	$97.1M+15.6%	$84.0M
Total Equity	$130.3M+41.5%	$92.1M+72.4%	$53.4M+147.3%	$21.6M+983.4%	-$2.4M+58.9%	-$6.0M
Retained Earnings	-$1.3B+2.4%	-$1.3B+2.3%	-$1.3B+1.6%	-$1.4B0.0%	-$1.4B-2.2%	-$1.3B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$216.3M+6.6%	$202.9M+4.1%	$194.9M-0.6%	$196.2M-8.0%	$213.3M-3.3%	$220.7M+7.7%	$205.0M-4.3%	$214.1M
Current Assets	$162.7M+13.3%	$143.6M+5.1%	$136.6M+3.1%	$132.5M-10.3%	$147.7M-5.8%	$156.8M+13.9%	$137.7M-3.7%	$143.0M
Cash & Equivalents	$29.6M-44.6%	$53.5M-2.1%	$54.7M-13.3%	$63.0M-8.9%	$69.2M+2.9%	$67.3M+0.2%	$67.1M-12.5%	$76.8M
Inventory	$5.5M-41.8%	$9.5M+10.3%	$8.6M-1.8%	$8.8M+0.3%	$8.7M+226.4%	$2.7M-70.5%	$9.0M+27.5%	$7.1M
Accounts Receivable	$53.7M+59.9%	$33.6M+29.5%	$25.9M+2.9%	$25.2M-21.4%	$32.0M-41.4%	$54.6M+94.4%	$28.1M+14.3%	$24.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$86.0M-1.9%	$87.6M-2.9%	$90.2M-9.0%	$99.1M-18.3%	$121.2M-19.0%	$149.6M-4.4%	$156.5M-4.1%	$163.2M
Current Liabilities	$81.3M-1.8%	$82.7M+4.6%	$79.1M-8.7%	$86.7M-9.8%	$96.1M-12.9%	$110.4M+5.8%	$104.3M+6.2%	$98.2M
Long-Term Debt	$0	$0-100.0%	$10.9M+2.1%	$10.6M-51.0%	$21.7M-33.7%	$32.7M-25.1%	$43.7M-20.0%	$54.7M
Total Equity	$130.3M+13.1%	$115.3M+10.1%	$104.7M+7.8%	$97.1M+5.4%	$92.1M+29.6%	$71.1M+46.5%	$48.5M-4.9%	$51.0M
Retained Earnings	-$1.3B+1.0%	-$1.3B+0.7%	-$1.3B+0.4%	-$1.3B+0.2%	-$1.3B+1.4%	-$1.3B+1.5%	-$1.4B-0.3%	-$1.3B

PBYI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$41.8M+7.4%	$38.9M+44.1%	$27.0M+270.7%	-$15.8M-176.6%	$20.6M+2571.4%	$773K
Capital Expenditures	$71K+26.8%	$56K-60.0%	$140K	$0	$0-100.0%	$46K
Free Cash Flow	$41.7M+7.4%	$38.9M+44.6%	$26.9M+269.8%	-$15.8M-176.6%	$20.6M+2740.4%	$727K
Investing Cash Flow	-$36.2M-77.1%	-$20.4M-6.9%	-$19.1M-369.2%	$7.1M+165.3%	-$10.9M-132.6%	$33.4M
Financing Cash Flow	-$45.2M-33.5%	-$33.8M	$0-100.0%	$12.2M+138.3%	-$31.9M-221.5%	-$9.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$14.4M+48.8%	$9.7M-31.2%	$14.1M+289.9%	$3.6M-76.9%	$15.6M+41.4%	$11.0M+974.8%	$1.0M-90.9%	$11.2M
Capital Expenditures	-$36K-238.5%	$26K+30.0%	$20K-67.2%	$61K+281.3%	$16K-20.0%	$20K0.0%	$20K	$0
Free Cash Flow	$14.4M+48.8%	$9.7M-31.3%	$14.1M+296.0%	$3.6M-77.2%	$15.6M+41.5%	$11.0M+994.1%	$1.0M-91.0%	$11.2M
Investing Cash Flow	-$27.0M-5431.4%	$506K+104.5%	-$11.2M-834.7%	$1.5M+166.0%	-$2.3M-995.8%	$259K-63.2%	$703K+103.7%	-$19.1M
Financing Cash Flow	-$11.3M0.0%	-$11.3M-1.2%	-$11.2M+1.1%	-$11.3M0.0%	-$11.3M-1.3%	-$11.2M+1.3%	-$11.3M	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PBYI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	74.5%+2.5pp	72.1%-1.3pp	73.4%-2.4pp	75.8%+1.0pp	74.8%-7.7pp	82.5%
Operating Margin	16.3%+2.9pp	13.4%-0.4pp	13.9%+3.5pp	10.4%+9.9pp	0.5%+14.0pp	-13.5%
Net Margin	13.6%+0.5pp	13.1%+4.0pp	9.2%+9.2pp	0.0%+11.5pp	-11.5%+15.1pp	-26.7%
Return on Equity	23.9%-9.0pp	32.9%-7.5pp	40.4%+40.4pp	0.0%	N/A	N/A
Return on Assets	14.4%+0.2pp	14.2%+4.8pp	9.4%+9.4pp	0.0%+12.8pp	-12.8%+11.7pp	-24.6%
Current Ratio	2.00+0.5	1.54-0.0	1.57-0.2	1.73+0.5	1.280.0	1.28
Debt-to-Equity	0.00-0.2	0.24-1.0	1.23-3.3	4.55+44.2	-39.69-25.6	-14.12
FCF Margin	18.3%+1.4pp	16.9%+5.5pp	11.4%+18.3pp	-6.9%-15.1pp	8.2%+7.8pp	0.3%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	69.3%-8.3pp	77.6%+1.1pp	76.5%-0.5pp	77.1%+0.6pp	76.4%+12.6pp	63.9%-13.5pp	77.4%+1.9pp	75.5%
Operating Margin	22.7%+5.1pp	17.6%+4.9pp	12.7%+4.0pp	8.7%-14.0pp	22.6%-4.8pp	27.4%+32.0pp	-4.6%+0.6pp	-5.3%
Net Margin	17.8%+1.6pp	16.2%+5.1pp	11.2%+4.7pp	6.5%-26.2pp	32.7%+7.4pp	25.2%+34.9pp	-9.6%+1.4pp	-11.0%
Return on Equity	10.3%+2.6pp	7.7%+2.1pp	5.6%+2.5pp	3.1%-17.9pp	21.0%-7.6pp	28.6%+37.9pp	-9.3%+0.1pp	-9.4%
Return on Assets	6.2%+1.9pp	4.4%+1.4pp	3.0%+1.5pp	1.5%-7.5pp	9.0%-0.2pp	9.2%+11.4pp	-2.2%+0.0pp	-2.3%
Current Ratio	2.00+0.3	1.740.0	1.73+0.2	1.530.0	1.54+0.1	1.42+0.1	1.32-0.1	1.46
Debt-to-Equity	0.000.0	0.00-0.1	0.100.0	0.11-0.1	0.24-0.2	0.46-0.4	0.90-0.2	1.07
FCF Margin	19.1%+1.3pp	17.7%-9.1pp	26.8%+19.1pp	7.7%-18.7pp	26.4%+12.7pp	13.7%+11.5pp	2.1%-23.6pp	25.7%

Similar Companies

Silence Therapeutics Plc SLN

$274.0M

Third Harmonic Bio Inc THRD

$242.8M

Proqr Therapeuti PRQR

$208.6M

Tonix Pharmaceut TNXP

$184.7M

Immutep IMMP

$47.3M

Frequently Asked Questions

What is Puma Biotechnology Inc's annual revenue?

Puma Biotechnology Inc (PBYI) reported $228.4M in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Puma Biotechnology Inc's revenue growing?

Puma Biotechnology Inc (PBYI) revenue declined by 0.9% year-over-year, from $230.5M to $228.4M in fiscal year 2025.

Is Puma Biotechnology Inc profitable?

Yes, Puma Biotechnology Inc (PBYI) reported a net income of $31.1M in fiscal year 2025, with a net profit margin of 13.6%.

What is Puma Biotechnology Inc's EBITDA?

Puma Biotechnology Inc (PBYI) had EBITDA of $48.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Puma Biotechnology Inc have?

As of fiscal year 2025, Puma Biotechnology Inc (PBYI) had $29.6M in cash and equivalents against $0 in long-term debt.

What is Puma Biotechnology Inc's gross margin?

Puma Biotechnology Inc (PBYI) had a gross margin of 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Puma Biotechnology Inc's operating margin?

Puma Biotechnology Inc (PBYI) had an operating margin of 16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Puma Biotechnology Inc's net profit margin?

Puma Biotechnology Inc (PBYI) had a net profit margin of 13.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Puma Biotechnology Inc's return on equity (ROE)?

Puma Biotechnology Inc (PBYI) has a return on equity of 23.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Puma Biotechnology Inc's free cash flow?

Puma Biotechnology Inc (PBYI) generated $41.7M in free cash flow during fiscal year 2025. This represents a 7.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Puma Biotechnology Inc's operating cash flow?

Puma Biotechnology Inc (PBYI) generated $41.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Puma Biotechnology Inc's total assets?

Puma Biotechnology Inc (PBYI) had $216.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Puma Biotechnology Inc's capital expenditures?

Puma Biotechnology Inc (PBYI) invested $71K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Puma Biotechnology Inc spend on research and development?

Puma Biotechnology Inc (PBYI) invested $62.1M in research and development during fiscal year 2025.

How many shares does Puma Biotechnology Inc have outstanding?

Puma Biotechnology Inc (PBYI) had 50M shares outstanding as of fiscal year 2025.

What is Puma Biotechnology Inc's current ratio?

Puma Biotechnology Inc (PBYI) had a current ratio of 2.00 as of fiscal year 2025, which is generally considered healthy.

What is Puma Biotechnology Inc's debt-to-equity ratio?

Puma Biotechnology Inc (PBYI) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Puma Biotechnology Inc's return on assets (ROA)?

Puma Biotechnology Inc (PBYI) had a return on assets of 14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Puma Biotechnology Inc's Altman Z-Score?

Puma Biotechnology Inc (PBYI) has an Altman Z-Score of -3.46, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Puma Biotechnology Inc's Piotroski F-Score?

Puma Biotechnology Inc (PBYI) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Puma Biotechnology Inc's earnings high quality?

Puma Biotechnology Inc (PBYI) has an earnings quality ratio of 1.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Puma Biotechnology Inc cover its interest payments?

Puma Biotechnology Inc (PBYI) has an interest coverage ratio of 5.6x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Puma Biotechnology Inc?

Puma Biotechnology Inc (PBYI) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.